Onglyza heart failure MDL sent to Kentucky

Heart failure lawsuits tied to diabetes drugs Onglyza and Kombiglyze XR will be consolidated in Kentucky federal court, a panel of judges has decided.

Ongylza and Kombiglyze XR are used by more than 100,00 Type 2 Diabetes patients in the U.S., and both drugs have been on the U.S. market since at least 2010. But it wasn’t until April 2016 that the FDA issued a safety announcement about these saxagliptin drugs and their link to heart failure, especially in patients who already suffer from heart or kidney disease.

Judges Send Onglyza Cases to Kentucky

The diabetes drug lawyers at Jones Ward argued in January at a hearing in Miami in favor of consolidating nearly 100 lawsuits involving Onglyza and Kombiglyze XR. Attorney Alex Davis told the seven-member Judicial Panel on Multidistrict Litigation that efforts to coordinate the cases were failing because manufacturers Bristol-Myers Squibb and AstraZeneca were failing to provide key documents related to the development and marketing of the two drugs. The panel issued an order on Feb. 2, 2018, stating that all Onglyza cases in federal court would be sent to Judge Karen Caldwell of the Eastern District of Kentucky in Lexington. Here is a portion of the order:

“Informal coordination among 84 cases scattered across the nation does not seem feasible …. Defendants concede that most cases involve allegations of heart failure, which is squarely in line with the results of the SAVOR study and the subsequent label change for Onglyza and Kombiglyze XR in April 2016.”

The lawsuits will become part of MDL 2809, a common procedure in mass tort cases that allows the parties to litigate certain pre-trial matters in front of a single judge in a more efficient and cost effective manner. An MDL is different than a class action, because the lawsuits remain individual cases, and eventually could be remanded back to their original jurisdictions for trial.

Onglyza Heart Failure Injuries

Jones Ward PLC has filed lawsuits in numerous federal courts on behalf of injured Onglyza users. Doctors are worried by reports of increased risk of heart failure for users of these incretin-based therapies. The lawsuits claim that drug companies such as Bristol-Myers Squibb and AstraZeneca failed to warn of the risk. Onglyza and Kombiglyze XR are both prescribed for Type 2 diabetes.

Scientific data show a statistically significant increase in the risk of heart failure with Onglyza. After receiving and reviewing disturbing findings from a clinical trial called SAVOR, the FDA requested the raw trial data, free from manipulation by Defendants, and performed its own analysis of the SAVOR data. Following the FDA’s detailed analysis and review of the SAVOR safety signal for hospitalization for heart failure, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee convened and voted 14 to 1 for the FDA to order a heart failure warning for these Saxagliptin drugs.

Jones Ward is currently evaluating potential Onglyza and Kombiglyze XR lawsuits. If you or someone you care about took Onglyza or Kombiglyze XR and was diagnosed with heart failure, our attorneys may be able to help you obtain financial compensation for any injury-related damages you incurred, including medical expenses, lost wages, pain and suffering, and more. Fill our our form today or call us toll free at 888-595-2922 for a free legal consultation. You may also email Attorney Alex Davis at alex@jonesward.com.

Sorry, comments are closed for this post.